Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
10
×
indiana blog main
indiana top stories
life sciences
national
10
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
10
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
biotech
cancer
eli lilly
drugs
regeneron pharmaceuticals
amgen
cancer immunotherapy
deals
food and drug administration
investing
medicare
nonalcoholic steatohepatitis
What
drug
10
×
fda
roundup
bio
cancer
drugs
new
prices
annual
approval
approved
attention
biotech
class
companies
long
medicine
meeting
migraine
news
patients
potential
trump
won
administration
afternoon
ahead
alzheimer’s
ambien
american
amgen
angry
anti
anticipated
aren’t
arguments
asco
assessed
attendees
awaited
Language
unset
Current search:
fda
×
national
×
" seattle blog main "
×
drug
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details